Skip to content

Clinical Study of Nalbuphine combined with Dexmedetomidine pretreatment on postoperative hyperalgesia induced by remifentanil

Clinical Study of Nalbuphine combined with Dexmedetomidine pretreatment on postoperative hyperalgesia induced by remifentanil

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043215
Enrollment
Unknown
Registered
2021-02-08
Start date
2021-02-18
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remifentanil-induced hyperalgesia

Interventions

Observation Group:saline solution
Group DN:Dexmedetomidine+Nalbuphine

Sponsors

Department of Anesthesiology, Wuhu Second Peoples Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.ASA I-II objects, 2. Subjects aged 20-65 years old, 3.18 = BMI = 29.

Exclusion criteria

Exclusion criteria: 1.Patients who are allergic to experimental drugs or have other contraindications 2.With serious heart,lung, liver, kidney and brain diseases 3.Patients with history of mental disorders, chronic pain, or abnormal pain perception 4.Recent history of pain, including surgery and trauma 5.Alcoholics who have been taking sedatives or dependence on sedatives for a long time 6.Pregnant and lactating women 7.For other reasons, they were not considered suitable subjects for study

Design outcomes

Primary

MeasureTime frame
Pain threshold;

Secondary

MeasureTime frame
Degree of pain;

Countries

China

Contacts

Public ContactLu Yao

The Second People's Hospital of Wuhu

luyao-mz@163.com+86 18956564060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 29, 2026